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The threat posed by severe congenital abnormalities related to Zika virus (ZKV) infec-
tion during pregnancy has turned development of a ZKV vaccine into an emergency. 
Recent work suggests that the cytotoxic T  lymphocyte (CTL) response to infection is 
an important defense mechanism in response to ZKV. Here, we develop the rationale 
and strategy for a new approach to developing cytotoxic T lymphocyte (CTL) vaccines 
for ZKV flavivirus infection. The proposed approach is based on recent studies using a 
protein structure computer model for HIV epitope selection designed to select epitopes 
for CTL attack optimized for viruses that exhibit antigenic drift. Because naturally pro-
cessed and presented human ZKV T cell epitopes have not yet been described, we 
identified predicted class I peptide sequences on ZKV matching previously identified 
DNV (Dengue) class I epitopes and by using a Major Histocompatibility Complex (MHC) 
binding prediction tool. A subset of those met the criteria for optimal CD8+ attack based 
on physical chemistry parameters determined by analysis of the ZKV protein structure 
encoded in open source Protein Data File (PDB) format files. We also identified candidate 
ZKV epitopes predicted to bind promiscuously to multiple HLA class II molecules that 
could provide help to the CTL responses. This work suggests that a CTL vaccine for 
ZKV may be possible even if ZKV exhibits significant antigenic drift. We have previously 
described a microsphere-based CTL vaccine platform capable of eliciting an immune 
response for class I epitopes in mice and are currently working toward in vivo testing 
of class I and class II epitope delivery directed against ZKV epitopes using the same 
microsphere-based vaccine.
Keywords: Zika vaccine, epitope, CtL vaccine, protein folding, dengue, flavivirus, computer model
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1. introdUCtion
As of Fall 2016, the Zika Virus (ZKV) pandemic continues 
its northward spread in the Americas. The CDC estimates at 
least 4,100 cases in the United States and up to 29,000 cases in 
Puerto Rico. Those cases in Puerto Rico include 672 pregnant 
women (1). Using a data-driven global stochastic epidemic 
model to project past and future spread of the ZKV in the 
Americas, it has been estimated that the large population 
centers of Florida, New York, and New Jersey will be seeing 
significant numbers of imported cases (acquired by travel) of 
ZKV infection (2) by the end of Fall 2016. In South America, 
the new case rate of ZKV infection is tapering off, however, 
researchers in Brazil warn that official statistics may signifi-
cantly underestimate the size of the ZKV epidemic based on 
improved serological tools that have become recently avail-
able. In any event, when a significant proportion of the popu-
lation is infected with a viral infection and become immune, 
the epidemic can migrate to an area with a larger susceptible 
individual pool. Given the alarming news that significant 
brain defects were detected in newborns of 42% women 
infected with ZKV during pregnancy, including the third tri-
mester (29%) (3), the public health threat of ZKV in pregnant 
women is even higher than expected before. Taken together, 
recent estimates put 1.65 million childbearing women in the 
Americas at risk of ZKV infection. As yet no phase II trials of 
a ZKV vaccine have been initiated. We review critical aspects 
of the unique pathogenesis of ZKV infection which will need 
to be considered when evaluating the efficacy of such vaccines 
and designing next iterations of possible ZKV vaccines to 
improve vaccine efficacy. In this article, we will also highlight 
details of the vaccines currently under consideration for 
Phase I and Phase II clinical trials, develop the argument that 
vaccines that evoke antibody responses need careful scrutiny, 
outline the rationale why our group is focusing on developing 
a “pure” CTL vaccine, and enumerate many of the challenges 
that will need to be overcome to develop an effective ZKV 
CTL vaccine.
1.1. Genome and protein structure of ZKV
ZKV is a small enveloped plus strand RNA virus belonging to the 
genus Flavivirus, which includes many human pathogenic viruses, 
such as Dengue virus (DNV), yellow fever virus (YFV), West Nile 
Virus (WNV), and hepatitis C virus (HCV). ZKV has a 10.8 kb 
RNA genome, containing a single open reading frame flanked by a 
5′-UTR (106 nt long) and a 3′-UTR (428 nt long). The open read-
ing frame encodes a polyprotein precursor, which is processed 
into three structural proteins [capsid (C), premembrane (prM), 
and envelope (E)] and seven non-structural proteins (NS1, NS2A, 
NS2B, NS3, NS4A, NS4B, and NS5). The viral E protein is the 
major surface glycoprotein of flavivirus, and the non-structural 
NS3 and NS5 encode essential enzyme activities for viral repro-
duction. The E protein is divided into three discernible domains 
(Domain I, Domain II, and Domain III). Domain I is involved in 
the envelope structure organization, and Domain II and Domain 
III are related to the monomers interaction and receptor binding, 
respectively (4).
1.2. protective immune responses  
to Flaviviruses: role of t Cells
Significant information is available about the protective role of 
T cell responses against other flaviviruses of clinical importance. 
Prevention of infection is achieved primarily by neutralizing 
antibodies but T cell responses (both CD4+ and CD8+) are of 
utmost importance for virus clearance. Cytotoxic CD8+ T cells 
are critical to eliminate virus-infected cells while CD4+ T cells 
provide help to cytotoxic CD8+ T cells and antibody production 
(5, 6). DNV-specific CD8+ T cells play a protective role in natural 
DNV infection both in humans and in animal models (7) and 
polyfunctional CD8+ responses are associated with protection 
against disease (8). CD8+ T  cell immunity has been shown to 
be protective against WNV infection (9). Vaccination with a 
tetravalent DNV vaccine elicits CD8+ T  cell responses against 
highly conserved epitopes (10). Similar, the live-attenuated 
17D-based YFV vaccine elicits potent and long-lasting CD8+ 
T  cell responses (11–13). Progress toward understanding the 
role of CD4+ T cell immunity in flavivirus infection is recent. 
YFV 17D-204 vaccination and adoptive transfer experiments 
demonstrate that CD4+ T cells contributed to protection against 
virulent YFV (14). Similar CD4+ responses have been found to 
be critical for protection against DNV challenge (15) and for the 
prevention of encephalitis during WNV infection (16). More 
recently, the CTL response in a murine ZKV model has shown 
to be crucial for protection against ZKV infection, both in CD8 
depletion experiments in mice and passive transfer of memory 
CD8+ T cells to naive mice exposed to infection. Furthermore, 
deletion of the CD8a−/− gene leads to 100% death after infec-
tion. This CD8+ T cell response is cytotoxic, polyfunctional, and 
targeted to several H-2D-restricted epitopes (17).
2. speCiFiC potentiaL adVantaGes  
oF CtL VERSUS antiBody VaCCine 
For ZKV
2.1. Caveats of antibody-inducing  
ZKV Vaccines
Following the acute phase infection of ZKV (with or without 
clinical symptoms), the persistence of biomarkers of ZKV infec-
tion (e.g., viral RNA in semen) suggest that some cells may be 
chronically infected. The wide distribution of types and anatomi-
cal locations of cells permissive for ZKV infection, sometimes 
beyond the easy reach of antibodies (e.g., blood–brain barrier), 
suggest that a cell mediated immune response will be critical for 
immune surveillance of chronically infected cells. While there 
can be little doubt that a ZKV vaccine stimulating a neutralizing 
antibody response will be a key resource in limiting viremia dur-
ing the acute phase of ZKV infection, there are some concerns 
regarding the exact nature of the antibody response provoked. 
The exact pathological mechanism which drives Guillain–Barré 
syndrome (GBS) remains unknown although there seems to a 
general consensus that antiglycolipid antibodies play an impor-
tant role, although not every GBS patient develop this type of 
antibody. As discussed earlier, there is an increased incidence 
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of GBS associated with ZKV infection (18, 19), but it is not known 
whether antiganglioside antibodies have a role in this specific 
comorbidity of ZKV infection. Each of the four different DNV 
serotypes (DNV 1–4) provoke cross-reactive antibody responses 
that may contribute to the increased disease severity observed 
following subsequent infection with a different serotype. The first 
DNV infection is either subclinical or result in a mild disease, 
and results in long lasting immunity to the serotype. The next 
DNV infection, if initiated by a different serotype, can induce 
severe, potentially lethal disease termed Dengue hemorrhagic 
fever/Dengue shock syndrome (20, 21). The immunopathogen-
esis of severe disease is not completely understood. One model, 
termed antibody-dependent enhancement (ADE), works as 
follows: anti-DNV antibodies evoked by the primary infection, 
which were once neutralizing but are not with the current 
serotype, bind the second serotype viral particles and promote 
antibody mediated phagocytosis by myeloid antigen-presenting 
cells which in turn become infected serving as a future reservoir 
for infectious virions with impaired functional activity (22). Of 
note are recent reports demonstrating that preexisting anti DNV 
abs can enhance ZKV infection (23, 24). Conversely, preexisting 
serum anti-ZKV antibodies were able to enhance DNV infection 
in vitro (25). This is due to the high serological crossreactivity 
between both flaviviruses which may not be cross-neutralizing. 
This crossreactivity is so relevant that it has delayed the develop-
ment of highly specific, non-DNV crossreactive serodiagnostic 
tests for ZKV infection. An additional concern for flavivirus 
vaccination-induced pathogenic antibodies in humans came 
from the recent reports of severe DNV breakthrough infections 
requiring hospitalization, after vaccination of seronegative 
volunteers with an antibody-inducing DNV attenuated virus 
tetravalent vaccine (Dengvaxia®), a phenomenon possibly 
related to ADE (26). This is a special concern since epidemics of 
both flaviviruses occur simultaneously in the same regions (27). 
Their research using a mouse model exhibiting much of the same 
symptoms/pathology of Dengue fever in humans, concluded 
“a sub-protective humoral response may, under some circum-
stances, have pathological consequences.” This group has since 
shifted their focus to inducing CD8+ T cell-mediated immunity 
to DNV (7, 28–31). Furthermore, the possibility that preexisting 
non-neutralizing anti-ZKV antibody-dependent enhancement 
could facilitate infection of fetal–mother interface tissues and 
contribute to fetal ZKV infection has not been excluded yet. Of 
note, currently studied ZKV candidate vaccines currently in the 
pipeline, either in the preclinical or phase I trial (one ongoing 
trial) phases, aim to elicit antibodies and are all based on whole 
envelope proteins, or whole inactivated or live attenuated virus 
(32). Preclinical studies using vaccines encoding whole ZKV 
preM/E proteins in DNA form, using adenovirus vectors, or 
whole inactivated ZKV in non-human primate models have been 
able to elicit neutralizing antibodies and protection after ZKV 
challenge (33, 34).
Taken together, these findings suggest caution in needed in the 
development of whole protein ZKV vaccines where evoked anti-
body responses that are not neutralizing may possibly enhance 
infection or be pathogenic (i.e., autoimmune) or could facilitate 
infection of maternal–fetal interface tissue.
2.2. epitope-Based t Cell Vaccines
Given the concerns with antibody-inducing flavivirus vaccines, 
one possible alternative would be to harness the power of the 
T cell immune response in protecting against flavivirus infection, 
as mentioned above. A recent report has shown that CD8+ T cell 
prevent antigen induced antibody-dependent enhancement 
of Dengue disease in a murine model and several studies have 
identified DNV T  cell epitopes appropriate for inclusion in a 
T  cell-based vaccine (31, 35–38). Another recent study shows 
the critical role of CTL response for protection against ZKV 
infection in a mouse model; this article identifies ZKV H-2D 
restricted epitopes recognized by CD8+ T  cells from infected 
mice (17). Recent clinical trials have demonstrated the efficacy 
of T-cell-inducing vaccines against a number of diseases (39), 
but immunization with whole proteins may favor responses to 
regions subject to antigenic drift and immune escape. A way to 
counteract this is to focus the response into specific desirable 
epitopes. The T cell epitope-based vaccine approach may target 
the immune response only to desirable and relevant epitopes, 
instead of the whole protein. Relevant epitopes include those 
that come from conserved viral protein regions, and/or where 
mutations could lead to reduced viral fitness, and those that bind 
to multiple MHC variant molecules—thus potentially recognized 
by the majority of the target population—while avoiding regions 
that are poorly immunogenic, variable and subject to antigenic 
drift, or that could cause a harmful response (40). These targeted 
immune responses could lead to increased potency, as well as 
increasing safety (41, 42). There are several ongoing clinical trials 
of T cell epitope-based Influenza vaccines aiming to be universal 
vaccines (43). Mapping and selection of potential immunogenic 
T cell epitopes is a crucial step that may be performed either with 
the aid of bioinformatics tools and experimental confirmation or 
by empirical approach using peptide library spanning the antigen 
full sequence.
2.3. antigenic drift: parallels to Chronic 
HiV infection and implications for Vaccine 
design
In chronic HIV infection there exists a reservoir of latent, tran-
scriptionally silent viral infection within the resting memory 
CD4+ T  cell compartment and specific myeloid lineage cells 
(e.g., CD14+/CD16+ monocytes) [reviewed in Ref. (44, 45)]. 
The resting CD4+ memory cells have long life spans, can remain 
quiescent, and similar to some of the ZKV tissue targets such 
placental, neuronal, and gonadal tissues as recently described 
in mice (46), may reside in immune-privileged sites such as the 
B  cell follicle of lymph nodes, allowing escape from existing 
immune surveillance mechanisms (47). While the mechanism 
that triggers active replication in HIV+ CD4+ memory cells is 
poorly understood, interruption of antiretroviral therapy is asso-
ciated with the resumption of viral replication. Unfortunately, 
preexisting HIV-1-specific CD8+ T cell responses have shown to 
be ineffective [reviewed in Ref. (48)] due to viral evolution of CTL 
epitopes, resulting in a limited repertoire of effective of cytotoxic 
T  cell-mediated immune responses (49) and progression to 
AIDS. In HIV infection there are selection pressures exerted by 
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the cellular immune system which result in antigenic drift in new 
virons (50).
A recent murine model study has demonstrated the potential 
importance of the CTL response to ZKV infection where H-2D 
restricted CTL epitopes were identified (17). Studies of HIV 
specific CTL responses in a subset of HIV+ individuals may 
also prove informative. HIV controllers (i.e., individuals who 
are HIV+ yet maintain low viral loads and do not progress to 
AIDS) have been carefully studied (51). HIV controller status is 
associated with the ability to develop CTL responses to regions of 
HIV proteins critical for maintenance of their structure–function 
(and viral fitness). Pereyra et al. (51) demonstrated that it may be 
possible to predict CTL class I epitopes favored by HIV control-
lers and suggested that CTL vaccines designed to evoke cellular 
immune responses to MHC class I restricted epitopes found 
within viral protein regions resistant to antigenic drift could 
lead to improved efficacy of HIV vaccines perhaps mimicking 
what happens naturally in HIV controllers. Our group has been 
inspired by these studies and has selected this general approach 
in the development of a CTL vaccine for ZKV.
Flaviviruses mutate in response to immune system pressure, 
both by antibodies and T cells. It has been reported that HLA 
class I-binding residues of a CD8+ T cell epitope encompassing 
the conserved catalytic site of DNV NS3 protease suffer varia-
tion that can abrogate HLA class I binding, suggesting evasion 
of DNV from a specific CD8+ T cell response by antigenic drift 
(52). Antigenic drift in ZKV has not been thoroughly studied, but 
a phylogenetic analysis of contemporary human isolates show a 
common ancestor and as many as 34 amino acid substitutions 
relative to the common ancestors with most of the variation con-
tained within the prM protein (53, 54), suggesting that ZKV does 
not undergo viral evolution as fast as HIV does. However, a recent 
phylogenetic study on 17 whole ZKV genomes from human iso-
lates in the present epidemic has shown the mutation rate varies 
between 12 and 25 bases (0.12–0.25% of the polyprotein) per year 
since the 2013 Polynesia outbreak. The latest sequence shows 64 
mutations; and overall, 62 non-synonymous amino acid changes 
were observed among all sequences analyzed, demonstrating that 
the ZKV continues to mutate at a rapid rate during the current 
epidemic (55). The rationale of focusing CTL attack to ZKV 
protein regions that are “intolerant” to amino acid substitutions 
thus remains sound.
2.4. ZKV HLa Class i epitope 
identification: HLa Binding and structural 
entropy
Human class I epitopes have not yet been formally identified 
for ZKV. Some authors have published ZKV MHC class II 
epitope prediction based on MHC binding search engines alone 
(35, 56, 57). In order to generate a realistic list of MHC-1 binding 
peptides on ZKV E and M proteins, not only did we use a binding 
prediction tool, but we also performed matching known DNV 
class I epitopes to peptides on ZKV. This is warranted due to the 
antigenic similarity of DNV and ZKV, which display 44–68% 
sequence identity, as well as the reported crossreactivity to ZKV 
of DNV envelope-specific antibodies (58). An additional layer of 
identification was the structural entropy analysis described in the 
next section.
We generated the predicted ZKV epitope list using the 
sequence of ZKV Strain H/PF/2013 (GenBank Accession number: 
KJ776791.2) (59). This strain was isolated from an infected patient 
during the French Polynesia epidemic in 2013–2014. The E and 
M protein amino acid sequences were run through the MHC-I 
Binding Predictions tool available on IEDB (60). This tool combines 
data from multiple prediction methods, which include artificial 
neural networks stabilized matrices. Choosing only those alleles 
that occur in at least 1% of the human population, we generated a 
list of predicted epitopes for MHC-A and B alleles. Percentile rank 
is calculated by comparing a given predicted peptide’s IC50 (con-
centration of the query peptide which inhibits 50% of a reference 
peptide binding) against those of a random set drawn from (61) 
where smaller rank indicates higher affinity. The highest ranking 
MHC-A and -B alleles are presented in Tables 1 and 2.
In order to maximize matching known DNV class I epitopes 
against the ZKV sequences, we were indiscriminate with respect 
to the DNV strain sequences. We used epitope sequence data from 
all of DNV strains 1–4, as downloaded from IEDB. Alignments 
between predicted ZKV epitopes and DNV were calculated using 
MAFFT (62) and webPRANK (63).
A recent study by Stettler (58) indicated ZKV/DNV cross-
recognition observed for antibodies may not also be present for 
T-cell epitopes. Because more work is needed on this topic, and 
in order to analyze a larger set of potential ZKV epitopes, the 
class I epitopes listed in Tables 1 and 2 are initially predicted, and 
only afterward aligned to DNV. Allowing for sequence divergence 
between DNV and ZKV, as well as keeping in mind the antigenic 
divergence between strains of ZKV, we did not require strict 
conservation between the predicted ZKV epitopes and the DNV 
epitopes they were compared to. As such, non-homologous but 
predicted epitopes were included in these tables. There are no 
table entries for epitopes matched to DNV but not predicted. 
Reported HLA specificities refer specifically to ZKV epitope 
predictions.
2.4.1. Computing Structural Entropy to Select Class I 
Epitopes for a CTL Vaccine
X-ray crystallography can be used to generate a PDB file con-
taining a complete mathematical representation of the three-
dimensional properties of a protein (64). Software is available 
which can take a PDB file as input and predict changes in the 
protein’s three-dimensional structure after specified amino acid 
substitutions. One example of such a program is FoldX, which 
compute whole-protein free energy changes resulting from these 
specified amino acid changes (65).
Pereyra-Heckerman described an index they call structural 
entropy (SE) which codifies the extent to which a free energy 
change will occur after CTL escape at that epitope (51). A low 
SE indicates that at least one amino acid position in an epitope, a 
relatively high change in the protein’s free energy is expected to 
occur after mutations to one or more amino acids in that epitope. 
They analyzed class I epitope targets preferred by HIV controllers 
and reported that these individuals have a statistically significant 
preference to attack class I epitopes associated with a low SE.
taBLe 2 | Structural entropy (SE) calculated by the authors for DNV homologous and/or MHC binding predicted class I epitopes on ZKV M.
epitope SE source start stop 1° allele 2° allele %RankΔ 1° ↔ 2°
VMILLIAPA 1.83 Predicted 65 74 HLA-A*30 HLA-B*15 0.45
LVMILLIAPA 1.87 Dengue/Predicted 64 73 HLA-A*02 HLA-B*08 2.75
YLVMILLIA 1.89 Dengue/Predicted 63 71 HLA-A*02 HLA-B*35 1.75
VMILLIAPAY 1.93 Predicted 65 74 HLA-A*30 HLA-B*15 0.45
IYLVMILLI 2.02 Dengue/Predicted 62 70 HLA-A*23 HLA-B*51 0.2
ALAAAAIAWL 2.24 Predicted 43 52 HLA-A*02 HLA-B*15 4.2
SQKVIYLVM 2.26 Dengue/Predicted 58 66 HLA-B*15 HLA-A*30 3.8
LLGSSTSQKV 2.25 Dengue/Predicted 52 61 HLA-A*02 HLA-B*51 17.35
TSQKVIYLV 2.33 Dengue/Predicted 56 65 HLA-A*68 HLA-B*57 0.55
LIRVENWIFR 2.37 Dengue/Predicted 29 38 HLA-A*31 HLA-B*57 31.25
VTLPSHSTR 2.58 Predicted 2 11 HLA-A*11 HLA-B*57 6.55
LPSHSTRKL 2.65 Predicted 3 12 HLA-B*07 HLA-A*02 4.65
SQTWLESREY 2.79 Predicted 16 25 HLA-B*15 HLA-A*30 1.45
RSQTWLESR 2.81 Predicted 15 23 HLA-A*31 HLA-B*57 6.25
KLQTRSQTW 2.84 Predicted 11 19 HLA-A*32 HLA-B*57 0.2
Start-Stop positions are relative to the ZKV M protein. %RankΔ reflects the absolute value of the difference between the best fit, primary (1°), and secondary (2°) allele percentile 
rank. Larger numbers for %RankΔ indicate a larger preference for the 1° allele.
taBLe 1 | Structural entropy (SE) calculated by the authors for DNV homologous and/or MHC binding predicted class I epitopes on ZKV E.
epitope SE source start stop 1° allele 2° allele %RankΔ 1° ↔ 2°
ALGGVLIFL 1.57 Dengue/Predicted 490 498 HLA-A*02 HLA-B*58 6.9
LTMNNKHWLV 1.73 Dengue/Predicted 204 213 HLA-A*02 HLA-B*08 1.45
GLFGKGSLV 1.78 Dengue/Predicted 106 114 HLA-A*02 HLA-B*08 16.7
TMNNKHWLV 1.84 Dengue/Predicted 205 213 HLA-A*02 HLA-B*08 1.55
YYLTMNNKHW 1.86 Dengue/Predicted 202 211 HLA-A*23 HLA-B*53 0.4
QEGAVHTAL 1.89 Dengue/Predicted 261 269 HLA-B*40 HLA-A*32 23.8
AVHTALAGA 1.96 Dengue/Predicted 264 272 HLA-A*30 HLA-B*07 1.6
YSLCTAAFTF 1.98 Dengue/Predicted 305 314 HLA-A*23 HLA-B*53 0.3
KEWFHDIPL 2.08 Dengue/Predicted 215 223 HLA-B*40 HLA-A*02 8.3
SQILIGTLLM 2.09 Dengue/Predicted 464 473 HLA-B*15 HLA-A*26 2.25
SYSLCTAAF 2.10 Dengue/Predicted 304 312 HLA-A*23 HLA-B*15 2.4
TPHWNNKEAL 2.13 Dengue/Predicted 233 242 HLA-B*07 HLA-A*23 46.25
ILIGTLLMW 2.13 Dengue/Predicted 466 474 HLA-B*57 HLA-A*33 42.65
DTAWDFGSV 2.13 Dengue/Predicted 426 434 HLA-A*68 HLA-B*51 12.8
LALGGVLIF 2.14 Dengue/Predicted 489 497 HLA-B*53 HLA-A*23 1.5
HKEWFHDIPL 2.15 Dengue/Predicted 214 223 HLA-B*40 HLA-A*32 0.45
MAVLGDTAW 2.16 Dengue/Predicted 421 429 HLA-B*53 HLA-A*32 5.2
RMAVLGDTAW 2.17 Dengue/Predicted 420 429 HLA-B*58 HLA-A*24 3.9
ILIGTLLMWL 2.17 Dengue/Predicted 466 475 HLA-A*02 HLA-B*15 5.5
VSYSLCTAAF 2.18 Dengue/Predicted 303 312 HLA-A*24 HLA-B*15 1.25
RLKGVSYSL 2.20 Dengue/Predicted 299 307 HLA-A*32 HLA-B*08 0.3
FKSLFGGMSW 2.28 Dengue/Predicted 453 462 HLA-B*58 HLA-A*23 3.5
KSLFGGMSW 2.28 Dengue/Predicted 454 462 HLA-B*57 HLA-A*32 0.15
KMMLELDPPF 2.33 Predicted 373 382 HLA-A*02 HLA-B*44 0.4
EFKDAHAKR 2.61 Dengue/Predicted 244 252 HLA-A*33 HLA-B*08 57.8
Start-Stop positions are relative to the ZKV E protein. %RankΔ reflects the absolute value of the difference between the best fit, primary (1°) and secondary (2°) allele percentile rank. 
Larger numbers for %RankΔ indicate a larger preference for the 1° allele.
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Identifying SE may be a key criterion for picking class I epitope 
CTL attack points especially for vaccines targeting pathogens that 
exhibit viral escape due to antigenic drift. Designing vaccines that 
focus cellular immunity toward these structurally critical regions 
of proteins may prove advantageous. Pereyra-Heckerman’s obser-
vation that HIV controllers preferentially target epitopes with a 
low SE suggests that it may be possible to design vaccines based 
entirely on an in silico analysis of the protein structure.
SE is calculated using a four-step process. First, a 20-element 
free energy change vector is created for each amino acid position 
within each class I epitope codifying the free energy change 
computed after each of all possible 20 amino acid substitutions 
at that amino acid position. Note that one of those substitutions 
will be the amino acid for itself resulting in a free energy change of 
“zero” for one of the entries in the 20-element free energy change 
vector. Second, each 20-element free energy change vector associ-
ated with each amino acid in the epitope is converted into a 20 
element Boltzmann probability distribution. A particularly high 
Boltzmann distribution entry indicates that there is a relatively 
high probability of that particular amino acid occurring at that 
A B
C
E F
D
FiGUre 1 | Three-dimensional ribbon view of ZKV E and M with moving-window-calculated SE values shown in heat map format. Note that the color coded SE 
regions do not represent SE values for specific epitope sequences.
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position. The first and second steps are implemented in equa-
tion (1) taken from Pereyra-Heckerman. Third, each Boltzmann 
distribution is converted into a single Shannon entropy value 
shown in Pereyra-Heckerman equation  (2). A Low Shannon 
entropy indicates a Boltzmann distribution with at least one entry 
significantly higher than the others, indicating a relatively high 
preference for the wild type. Fourth, the SE is calculated by taking 
the mean of the Shannon entropies for the individual amino acids 
in the epitope.
 
p E f e
eij ij
ddG
k
ddG
ij
ik
= | | =
−| |
=
−| |∑ 1
20
 
(1)
 
E H p pi
j
ij ij| | = −
=
∑
1
20
ln( )
 
(2)
In systems with many possible energy states, the Boltzmann 
distribution is typically used to compute the relative probability 
of each energy state occurring. The Boltzmann distribution is 
used here, in the context of amino acid substitutions, to estimate 
the probability of each substitution occurring by considering how 
much each substitution changes the protein’s energy relative to 
the wild type. We assume that the wild type is the most likely state, 
and compute the Boltzmann distribution from the free energy 
changes relative to the wild type, generating a distribution of 
probabilities for each substitution. Amino acids that do not cause 
large energy changes will have a high probability, large-valued 
entry in the Boltzmann distribution, and mutations which cause 
large energy changes will have low Boltzmann values. We can 
think of the values in the Boltzmann Distribution as measuring 
the “naturalness” of each mutation at the given site.
The ZKV structural entropy data was generated using the 
PDB file (64) uploaded to RCSB by Sirohi et  al. in March of 
2016 (66). Protein structure data was available for ZKV E and 
M proteins only. The original DNA sequence used to generate 
this protein structure was based on the ZKV Strain H/PF/2013 
(GenBank Accession number: KJ776791.2) (59). The ZKV 
E protein has been identified as the main source of H-2D-
restricted MHC class I epitopes recognized by CD8+ T  cells 
from ZKV-infected mice (17).
SE data for class I epitopes identified on ZKV E are shown in 
Table 1 and for ZKV M in Table 2. Qualitative heat maps showing 
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SE values computed using moving windows across all amino 
acids in ZKV E and ZKV M are shown in Figure 1. These heat 
maps are not based on the specific epitope sequences identified in 
the tables. They are qualitative and are intended to show the dis-
tribution of SE values throughout the proteins. Note that low SE 
regions, shown in blue, are in the minority. By raking the epitopes 
in order of SE in Tables 1 and 2, we list the epitopes predicted to 
be the best CTL targets based on Pereyra-Heckerman first.
2.5. Mapping of potential epitopes  
in ZKV Capable of Binding to Multiple  
HLa Class ii Molecules
The rational selection of CD4+ T cell epitopes in vaccine formula-
tion is crucial for successful application of vaccination strategies 
that focus on induction of CD8+ T cell immunity, given the role of 
CD4+ T cell response in long-term maintenance of CD8+ T cell-
dependent protective immunity. Recently, CD4+ T  cells with 
cytotoxic features have been identified in PBMC from patients 
with chronic viral infections (67–70). Bioinformatics tools for 
identification of HLA class II epitopes have been reviewed by 
Ref. (71). The TEPITOPE HLA-DR binding prediction algorithm 
(72) and the derived ProPred algorithm (73) use the concept 
that each HLA-DR pocket in the antigen-binding groove can be 
characterized by “pocket profiles,” a quantitative representation 
of the interaction of all natural amino-acid residues with a given 
pocket, creating a matrix incorporated in the TEPITOPE and 
ProPred softwares. For each HLA-DR specificity, the algorithms 
generated a binding score corresponding to the algebraic sum of 
the strength of interaction between each residue and pocket, 
which correlated with binding affinity. Peptide scores along 
a scanned protein sequence are normalized for each HLA-DR 
as the proportion of the best binder peptides (74). Since the 
software predicts binding to a significant number of HLA-DR 
specificities (25 in the case of TEPITOPE, 51 for PROPRED), it 
is also capable of predicting promiscuous peptide ligands each 
capable of binding to multiple HLA class II variant molecules 
(58). The TEPITOPE prediction algorithm has been successfully 
applied to the identification of dozens of promiscuous T  cell 
epitopes frequently recognized in 59 antigenic proteins from 
several human pathogens including viruses, bacteria, protozoa, 
fungi, and helminths (HIV, SIV, CMV. M. tuberculosis, P. vivax, 
P. brasiliensis, S. mansoni), and in  silico prediction correlated 
with promiscuity in HLA-binding assays and frequency of T cell 
recognition by exposed individuals (75). This has led to several 
epitope-based vaccines which were shown to be immunogenic 
using conventional or and HLA class II-transgenic mice (71, 76) 
and protective (77) in mice. The incorporation of a promiscu-
ous CD4+ T  cell epitope in a recombinant protein-based P. 
vivax vaccine led to significant increase in its immunogenicity 
(41). A recent study from our group in non-human primates 
showed that a HIV CD4+ T cell epitope-based DNA vaccine was 
highly immunogenic and induced significant responses to most 
encoded epitopes in all animals tested (unpublished observa-
tions). Vaccines encoding promiscuous peptides able to bind to 
multiple HLA-DR molecules may thus allow wide population 
coverage. Here, we used the TEPITOPE and ProPred algorithms 
to identify potential “promiscuous” CD4+ T cell epitopes—pre-
dicted to bind to multiple HLA-DR molecules—derived from 
conserved regions of ZKV majority/consensus E and M protein 
sequences from circulating strains in the recent epidemic in 
Brazil and Polynesia.
2.6. selection of ZKV sequences and 
promiscuous HLa Class ii epitope 
prediction
The amino acid sequences derived from the ZKV strains BeH-
818995 (Genbank accession number KU365777.1), BeH819015 
(Genbank accession number KU365778.1), BeH815744 (Gen-
bank accession number KU365780.1), BeH819966 (Genbank 
accession number KU365779.1), SPH2015 (Genbank acces-
sion number KU321639.1), and SSABR1 (Genbank accession 
number KU707826.1), isolated in Brazil; and the H/PF/2013 
strain (Genbank accession number KJ776791.2) isolated in 
French Polynesia were assembled and aligned with Clustal W 
(MegAlign, DNASTAR, Madison, WI, USA, Figure  2). We 
scanned the generated consensus sequence with the TEPITOPE 
and ProPred algorithms. We selected ZKV M and E peptides 
(Table  3) whose sequences were predicted to bind to at least 
2/3 out of the 25 or 51 HLA-DR molecules in the TEPITOPE 
or ProPred matrixes, respectively, corresponding to an inner 
nonamer core selected as the HLA binding motif with flank-
ing amino acids added when possible at either or both N- and 
C-terminal ends, to increase the efficiency of in  vitro peptide 
presentation to CD4+ T cells.
2.7. potential synthetic CtL Vaccine 
platforms for Class i and Class ii epitope 
delivery
H-2D-restricted class I epitopes, when injected intradermally 
without adjuvants, produce a weak immune response in 
C57BL/6 mice. Methods have been described for eliciting 
immune responses to class I. For example, the target epitopes 
are linked together as a “string of beads” (78). In another exam-
ple, the DNA corresponding to the desired string of epitopes is 
inserted in a modified vaccinia Ankara (MVA) vector. Immune 
responses have been elicited in mice using this technique (79). 
A DNA string has also been administered with electroporation 
(80). Immune responses in Macaques have been elicited in 
this manner (81). In order to add and subtract epitopes from 
the formulation used in these types of vaccines, new linker 
elements must be identified and proper presentation of the 
desired epitopes after “string-of-beads” processing by antigen-
presenting cells confirmed (82).
The use of a biodegradable, PLGA microsphere-based vaccine 
delivery platform allows one or more unmodified peptides to 
easily be incorporated into the vaccine formulation (83). The 
limitations of PLGA microsphere-based vaccines have been 
described in the literature. For example, double-emulsion sphere 
fabricating technologies may degrade the tertiary structure of the 
FiGUre 2 | Alignment of ZKV M (a) and E (B) proteins with epitope identification.
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taBLe 3 | Model-predicted class II epitopes on ZKV E and ZKV M proteins.
epitope id epitope sequence interacting HLa-dr alleles % predicted/51
M (58–77) SQKVIYLVMILLIAPAYSIR DRB1*0101, DRB1*0102, DRB1*0301, DRB1*0305, DRB1*0306, DRB1*0307, DRB1*0308, 
DRB1*0309, DRB1*0311, DRB1*0401, DRB1*0402, DRB1*0404, DRB1*0405, DRB1*0408, 
DRB1*0410, DRB1*0421, DRB1*0423, DRB1*0426, DRB1*0701, DRB1*0703, DRB1*0801, 
DRB1*0802, DRB1*0804, DRB1*0806, DRB1*0813, DRB1*0817, DRB1*1101, DRB1*1102, 
DRB1*1104, DRB1*1106, DRB1*1107, DRB1*1114, DRB1*1120, DRB1*1121, DRB1*1128, 
DRB1*1301, DRB1*1302, DRB1*1304, DRB1*1305, DRB1*1307 DRB1*1311, DRB1*1321, 
DRB1*1322, DRB1*1323, DRB1*1327, DRB1*1328, DRB1*1501, DRB1*1502, DRB1*1506, 
DRB5*0101, DRB5*0105
100
E (130–149) QPENLEYRIMLSVHGSQHSG DRB1*0101, DRB1*0102, DRB1*0301, DRB1*0305, DRB1*0309, DRB1*0401, DRB1*0402, 
DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0410, DRB1*0421, DRB1*0423, DRB1*0426, 
DRB1*0701, DRB1*0703, DRB1*0801, DRB1*0802, DRB1*0804, DRB1*0806, DRB1*0813, 
DRB1*0817, DRB1*1101, DRB1*1102, DRB1*1104, DRB1*1106, DRB1*1107, DRB1*1114, 
DRB1*1120, DRB1*1121, DRB1*1128, DRB1*1301, DRB1*1302, DRB1*1304, DRB1*1305, 
DRB1*1307, DRB1*1311, DRB1*1321, DRB1*1322, DRB1*1323, DRB1*1327, DRB1*1328, 
DRB1*1501, DRB1*1502, DRB1*1506, DRB5*0101, DRB5*0105
92
E (289–308) KCRLKMDKLRLKGVSYSLCT DRB1*0301, DRB1*0305, DRB1*0306, DRB1*0307, DRB1*0308, DRB1*0309, DRB1*0311, 
DRB1*0401, DRB1*0402, DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0410, DRB1*0421, 
DRB1*0423, DRB1*0426, DRB1*0801, DRB1*0802, DRB1*0804, DRB1*0806, DRB1*0813, 
DRB1*0817, DRB1*1101, DRB1*1102, DRB1*1104, DRB1*1106, DRB1*1107, DRB1*1114, 
DRB1*1120, DRB1*1121, DRB1*1128, DRB1*1301, DRB1*1302, DRB1*1304, DRB1*1305, 
DRB1*1307, DRB1*1311, DRB1*1321, DRB1*1322, DRB1*1323, DRB1*1327, DRB1*1328, 
DRB5*0101, DRB5*0105
86
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epitopes capable of binding to multiple HLA class II molecules 
could provide wide HLA and population coverage for such a 
vaccine which could be delivered using the synthetic, adjuvanted 
microsphere vaccine as outlined above or other techniques for 
epitope immunization that we discussed.
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delivered antigen due to exposure to solvents or high temperatures 
used during spray drying processes (84). In a previous report, 
we manufactured our microspheres avoiding double emulsion 
sphere manufacturing technology using a precision spray drying 
process that operates at room temperature (85).
In contrast to previous studies which incorporated only a sin-
gle peptide epitope in spheres (86), we showed that it was possible 
to elicit an immune response from each of two epitopes delivered 
simultaneously, when the two epitopes were loaded into the same 
spheres or different spheres.
This is an important consideration, especially because the 
HLA restricted nature of the class I epitopes being delivered will 
require the development of a “master vaccine” containing enough 
different peptide epitopes to cover a target population.
The fact that the majority of the epitopes listed in the first 
four rows of Tables 1 and 2 have the best predicted HLA match 
as HLA*02 suggests that a vaccine directed against these class 
I epitopes could readily tested in Brazil where the frequency 
of HLA A*02 frequency varies from 21.7 to 47.5% between 
states (87).
3. ConCLUdinG reMarKs
The search for rapid development of safe and effective vaccines 
against ZKV is a global public health emergency. Testing multiple 
vaccine platforms in parallel may speed up and increase the likeli-
hood of finding a good vaccine. We have proposed a rationale 
for ZKV epitope selection and design of T  cell epitope-based 
vaccine against ZKV virus. Selection of candidate ZKV structure-
constrained HLA class I epitopes able to bind an array of HLA 
class I supertypic molecules, and promiscuous class II T  cell 
10
Cunha-Neto et al. Approach for Synthetic Vaccine Design against Zika
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 640
reFerenCes
1. CDC. Zika Virus Case Counts in the US. (2016). Available from: http://www.
cdc.gov/zika/geo/unitedstates.html
2. Zhang Q, Sun K, Chinazzi M, Pastore-Pinotti A, Dean NE, Rojas DP, 
et  al. Projected spread of Zika virus in the Americas. bioRxiv (2016). 
doi:10.1101/066456
3. Brasil P, Pereira JP, Gabaglia J, Damasceno CR, Wakimoto LM, Nogueira R, 
et al. Zika virus infection in pregnant women in Rio de Janeiro – preliminary 
report. N Engl J Med (2016). doi:10.1056/NEJMoa1602412 
4. Ye Q, Liu Z, Han J, Jiang T, Li X, Qin C. Genomic characterization and phy-
logenetic analysis of Zika virus circulating in the Americas. Infect Genet Evol 
(2016) 43:43–9. doi:10.1016/j.meegid.2016.05.004 
5. Sant A, McMichael A. Revealing the role of CD4(+) T cells in viral immunity. 
J Exp Med (2012) 209(8):1391–5. doi:10.1084/jem.20121517 
6. Swain S, McKinstry K, Strutt. Expanding roles for CD4+ T cells in immunity 
to viruses. Nat Rev Immunol (2012) 12(2):136–48. doi:10.1038/nri3152 
7. Yauch L, Zellweger M, Kotturi M, Qutubuddin A, Sidney J, Peters B, et  al. 
A protective role for dengue virus-specific CD8+ T cells. J Immunol (2009) 
182(8):4865–73. doi:10.4049/jimmunol.0801974 
8. Weiskopf D, Bangs D, Sidney J, Kolla R, Silva AD, de Silva A, et al. Dengue virus 
infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated 
with protective immunity. Proc Natl Acad Sci U S A (2015) 112(31):E4256–63. 
doi:10.1073/pnas.1505956112 
9. Netland J, Bevan M. CD8 and CD4 T cells in West Nile virus immunity and 
pathogenesis. Viruses (2013) 5(10):2573–84. doi:10.3390/v5102573 
10. Weiskopf D, Angelo M, Bangs D, Sidney J, Paul S, Peters B, et al. The human 
CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine 
are directed against highly conserved epitopes. J Virol (2015) 89(1):120–8. 
doi:10.1128/JVI.02129-14 
11. Akondy R, Johnson L, Nakaya H, Edupuganti S, Mulligan M, Lawson B, et al. 
Initial viral load determines the magnitude of the human CD8 T cell response 
to yellow fever vaccination. Proc Natl Acad Sci U S A (2015) 112(10):3050–5. 
doi:10.1073/pnas.1500475112 
12. Bassi M, Kongsgaard M, Steffensen M, Fenger C, Rasmussen M, Skødt K, 
et al. CD8+ T cells complement antibodies in protecting against yellow fever 
virus. J Immunol (2015) 194(3):1141–53. doi:10.4049/jimmunol.1402605 
13. Marraco SF, Soneson C, Po G, Allard M, Maillard SA, Montandon N, 
et  al. Long-lasting stem cell-like memory CD8+ T  cells with a naïve-like 
profile upon yellow fever vaccination. Sci Transl Med (2015) 7(282):4111–6. 
doi:10.1126/scitranslmed.aaa3700 
14. Watson A, Lam L, Klimstra W, Ryman K. The 17D-204 vaccine strain-induced 
protection against virulent yellow fever virus is mediated by humoral immu-
nity and CD4+ but not CD8+ T cells. PLoS Pathog (2016) 12(7):e1005786. 
doi:10.1371/journal.ppat.1005786 
15. Chen H-W, Hu H-M, Wu S-H, Chiang C-Y, Hsiao Y-J, Wu C-K, et al. The 
immunodominance change and protection of CD4+ T-cell responses elicited 
by an envelope protein domain III-based tetravalent dengue vaccine in mice. 
PLoS One (2015) 10(12):e0145717. doi:10.1371/journal.pone.0145717 
16. Brien J, Uhrlaub J, Nikolich-Zugich J. West Nile virus-specific Cd4 T  cells 
exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient 
for antiviral protection. J Immunol (2008) 181(12):8568–75. doi:10.4049/
jimmunol.181.12.8568 
17. Ngono E, Vizcarra E, Tang W, Sheets N, Kim K, Gorman M, et al. Mapping 
and role of the CD8+ T  cell response during primary Zika virus infection 
in mice. Cell Host Microbe (2017) 21(1):35–46. doi:10.1016/j.chom.2016. 
12.010 
18. Cao-Lormeau V, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J, et al. 
Guillain-Barre syndrome outbreak associated with Zika virus infection in 
French polynesia: a case-control study. Lancet (2016) 387(10027):1531–9. 
doi:10.1016/S0140-6736(16)00562-6 
19. Parra B, Lizarazo J, Jimenez-Arango JA, Zea-Vera AF, Gonzalez-Manrique G, 
Vargas J, et al. Guillain-Barre syndrome associated with Zika virus infection 
in colombia. N Engl J Med (2016) 375(16):1513–23. doi:10.1056/NEJMoa 
1605564 
20. Guzman MG, Alvarez M, Halstead SB. Secondary infection as a risk factor for 
dengue hemorrhagic fever/dengue shock syndrome: an historical perspective 
and role of antibody-dependent enhancement of infection. Arch Virol (2013) 
158(7):1445–59. doi:10.1007/s00705-013-1645-3 
21. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, 
Vazquez S, et al. Neutralizing antibodies after infection with dengue 1 virus. 
Emerg Infect Dis (2007) 13(2):282–6. doi:10.3201/eid1302.060539 
22. Schmid M, Diamond MS, Harris E. Dendritic cells in dengue virus infection: 
targets of virus replication and mediators of immunity. Front Immunol (2014) 
5:647. doi:10.3389/fimmu.2014.00647 
23. Dejnirattisai W, Supasa P, Wongwiwat W, Rouvinski A, Barba-Spaeth G, 
Duangchinda T, et  al. Dengue virus serocross-reactivity drives antibody- 
dependent enhancement of infection with Zika virus. Nat Immunol (2016) 17: 
1102–8. doi:10.1038/ni.3515 
24. Paul LM, Carlin ER, Jenkins MM, Tan AL, Barcellona CM, Nicholson CO, 
et al. Dengue virus antibodies enhance Zika virus infection. bioRxiv (2016). 
doi:10.1101/050112
25. Kawiecki A, Christofferson R. Zika virus-induced antibody response 
enhances dengue virus serotype 2 replication in  vitro. J Infect Dis (2016) 
214(9):1357–60. doi:10.1093/infdis/jiw377 
26. Russell P, Halstead S. Challenges to the design of clinical trials for live- 
attenuated tetravalent dengue vaccines. PLoS Negl Trop Dis (2016) 10:8. 
doi:10.1371/journal.pntd.0004854 
27. Zellweger RM, Prestwood TR, Shresta S. Enhanced infection of liver 
sinusoidal endothelial cells in a mouse model of antibody-induced severe 
dengue disease. Cell Host Microbe (2010) 7(2):128–39. doi:10.1016/j.chom. 
2010.01.004 
28. Dudley DW, Aliota MT, Mohr EL, Weiler AM, Lehrer-Brey G, Weisgrau KL, 
et  al. A rhesus macaque model of Asian-lineage Zika virus infection. Nat 
Commun (2016) 7:12204. doi:10.1038/ncomms12204 
29. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B, 
et al. CD4+ T cells are not required for the induction of dengue virus-spe-
cific CD8+ T  cell or antibody responses but contribute to protection after 
vaccination. J Immunol (2010) 185(9):5405–16. doi:10.4049/jimmunol. 
1001709 
30. Zellweger RM, Tang WW, Eddy WE, King K, Sanchez MC, Shresta S. CD8+ 
T cells can mediate short-term protection against heterotypic dengue virus 
reinfection in mice. J Virol (2015) 89(12):6494–505. doi:10.1128/JVI.00036-15 
31. Zellweger R, Eddy WE, Tang WW, Miller R, Shresta S. CD8+ T cells prevent 
antigen-induced antibody-dependent enhancement of dengue disease in 
mice. J Immunol (2014) 193(8):4117–24. doi:10.4049/jimmunol.1401597 
32. Vaccine Pipeline Tracker. (2016). Available from: http://www.who.int/
immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
33. Abbink P, Larocca R, de La Barrera R, Bricault C, Moseley E, Boyd M, et al. 
Protective efficacy of multiple vaccine platforms against Zika virus challenge 
in rhesus monkeys. Science (2016) 353(6304):1129–32. doi:10.1126/science.
aah6157 
34. Dowd K, Ko S, Morabito K, Yang E, Pelc R, DeMaso C, et al. Rapid devel-
opment of a DNA vaccine for Zika virus. Science (2016) 354(6309):237–40. 
doi:10.1126/science.aai3197 
35. Alam A, Ali S, Ahamad S, Malik M, Ishrat R. From ZikV genome to vaccine: 
in  silico approach for the epitope-based peptide vaccine against Zika virus 
envelope glycoprotein. Immunology (2016) 149(4):386–99. doi:10.1111/
imm.12656 
36. Khan A, Miotto O, Heiny A, Salmon J, Srinivasan K, Nascimento E, et  al.  
A systematic bioinformatics approach for selection of epitope-based vaccine 
targets. Cell Immunol (2006) 244(2):141–7. doi:10.1016/j.cellimm.2007.02.005 
37. Sánchez-Burgos G, Ramos-Castañeda J, Cedillo-Rivera R, Dumonteil E. 
Immu nogenicity of novel dengue virus epitopes identified by bioinformatic 
analysis. Virus Res (2006) 153(1):113–20. doi:10.1016/j.virusres.2010.07.014 
38. Shi J, Sun J, Wu M, Hu N, Li J, Li Y, et al. Inferring protective CD8+ T-cell 
epitopes for NS5 protein of four serotypes of dengue virus Chinese isolates 
based on HLA-a, -b and -c allelic distribution: implications for epitope-based 
universal vaccine design. PLoS One (2015) 10(9):e0138729. doi:10.1371/
journal.pone.0138729 
39. Gilbert S. T-cell-inducing vaccines – what’s the future? Immunology (2012) 
135(1):19–26. doi:10.1111/j.1365-2567.2011.03517.x 
40. Borthwick N, Ahmed T, Ondondo B, Hayes P, Rose A, Ebrahimsa U, et al. 
Vaccine-elicited human T cells recognizing conserved protein regions inhibit 
HIV-1. Mol Ther (2014) 22(2):464–75. doi:10.1038/mt.2013.248 
41. Rosa D, Iwai L, Tzelepis F, Bargieri D, Medeiros M, Soares I, et  al. 
Immunogenicity of a recombinant protein containing the Plasmodium 
vivax vaccine candidate msp1(19) and two human CD4+ T-cell epitopes 
11
Cunha-Neto et al. Approach for Synthetic Vaccine Design against Zika
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 640
administered to non-human primates (Callithrix jacchus jacchus). Microbes 
Infect (2006) 8(8):2130–7. doi:10.1016/j.micinf.2006.03.012 
42. Soria-Guerra R, Nieto-Gomez R, Govea-Alonso D, Rosales-Mendoza S. 
An overview of bioinformatics tools for epitope prediction: implications on 
vaccine development. J Biomed Inform (2014) 53:405–14. doi:10.1016/j.jbi. 
2014.11.003 
43. Sridhar S. Heterosubtypic T-cell immunity to influenza in humans: chal-
lenges for universal T-cell influenza vaccines. Front Immunol (2016) 7:195. 
doi:10.3389/fimmu.2016.00195 
44. Kimata JT, Rice AP, Wang J. Challenges and strategies for the eradication 
of the HIV reservoir. Curr Opin Immunol (2016) 42:65–70. doi:10.1016/j.
coi.2016.05.015 
45. Abbas W, Tariq M, Iqbal M, Kumar A, Herbein G. Eradication of HIV-1 
from the macrophage reservoir: an uncertain goal? Viruses (2015) 7:1578–98. 
doi:10.3390/v7041578 
46. Govero J, Esakky P, Scheaffer S, Fernandez E, Drury A, Platt D, et al. Zika virus 
infection damages the testes in mice. Nature (2016) 540:438–42. doi:10.1038/
nature20556 
47. Connick E, Folkvord JM, Lind KT, Rakasz EG, Miles B, Wilson NA, et  al. 
Compartmentalization of simian immunodeficiency virus replication within 
secondary lymphoid tissues of rhesus macaques is linked to disease stage 
and inversely related to localization of virus-specific CTL. J Immunol (2014) 
193(11):5613–25. doi:10.4049/jimmunol.1401161 
48. Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes 
disease. AIDS Rev (2003) 5(3):172–7. 
49. Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, et al. Human 
immunodeficiency virus type 1-specific CD8+ T-cell responses during pri-
mary infection are major determinants of the viral set point and loss of CD4+ 
T cells. J Virol (2009) 83(15):7641–8. doi:10.1128/JVI.00182-09 
50. Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, et al. 
Features of recently transmitted HIV-1 clade c viruses that impact antibody 
recognition: implications for active and passive immunization. PLoS Pathog 
(2016) 12(7):e1005742. doi:10.1371/journal.ppat.1005742 
51. Pereyra F, Heckerman D, Carlson JM, Soghoian CK, Karel D, Goldenthal A, 
et  al. HIV control is mediated in part by CD8+ T-cell targeting of specific 
epitopes. J Virol (2014) 88(22):12937–48. doi:10.1128/JVI.01004-14 
52. Schein C, Zhou B, Braun W. Stereophysicochemical variability plots highlight 
conserved antigenic areas in flaviviruses. Virol J (2005) 2:40. doi:10.1186/ 
1743-422X-2-40 
53. Faria NR, Rdo SA, Kraemer MU, Souza R, Cunha MS, Hill SC, et al. Zika virus 
in the Americas: early epidemiological and genetic findings. Science (2016) 
352(6283):345–9. doi:10.1126/science.aaf5036 
54. Wang L, Valderramos SG, Wu A, Ouyang S, Li C, Brasil P, et al. From mos-
quitos to humans: genetic evolution of Zika virus. Cell Host Microbe (2016) 
19(5):561–5. doi:10.1016/j.chom.2016.04.006 
55. Logan I. Zika – how fast does this virus mutate? Dongwuxue Yanjiu (2016) 
37(2):110–5. doi:10.13918/j.issn.2095-8137.2016.2.110
56. Ashfaq U, Ahmed B. De novo structural modeling and conserved epitopes 
prediction of Zika virus envelop protein for vaccine development. Viral 
Immunol (2016) 29(7):1–8. doi:10.1089/vim.2016.0033 
57. Shawan M, Mahmud H, Hasan M, Parvin M, Rahman N, Rahman SMB. In 
silico modeling and immunoinformatics probing disclose the epitope based 
peptidevaccine against Zika virus envelope glycoprotein. Indian J Pharm Biol 
Res (2014) 2(4):44–57. 
58. Stettler K, Beltramello M, Espinosa DA, Graham V, Cassotta A, Bianchi S, 
et al. Specificity, cross-reactivity and function of antibodies elicited by Zika 
virus infection. Science (2016) 353(6301):823–6. doi:10.1126/science.aaf8505 
59. Zika-Strain. Complete Coding Sequence of Zika Virus from a French Polynesia 
Outbreak in 2013. (2014). Available from: https://www.ncbi.nlm.nih.gov/pmc/
articles/PMC4047448/
60. IEDB. IEDB MHC-I Binding Predictions Tool. (2013). Available from: http://
tools.iedb.org/mhci/reference/
61. UniProtKB/Swiss-Prot. (2016). Available from: https://www.ebi.ac.uk/uniprot
62. Katoh K, Misawa K, Kuma K, Miyata T. Mafft: a novel method for rapid 
multiple sequence alignment based on fast Fourier transform. Nucleic Acids 
Res (2002) 30(14):3059–66. doi:10.1093/nar/gkf436 
63. Löytynoja A, Goldman N. webPRANK: a phylogeny-aware multiple sequence 
aligner with interactive alignment browser. BMC Bioinformatics (2010) 
11:579. doi:10.1186/1471-2105-11-579 
64. RCSB PDB Policies and References. (2013). Available from: http://www.rcsb.
org/pdb/static.do?p=general_information/about_pdb/policies_references.
html
65. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The foldx web 
server: an online force field. Nucleic Acids Res (2005) 33:W382–8. doi:10.1093/
nar/gki387 
66. Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossman MG, et  al. The 
3.8Å resolution cryo-EM structure of Zika virus. Science (2016) 22:467–70. 
doi:10.1126/science.aaf5316 
67. Aslan N, Yurdaydin C, Wiegand J, Greten T, Ciner A, Meyer M, et  al. 
Cytotoxic CD4 T cells in viral hepatitis. J Viral Hepat (2006) 13(8):505–14. 
doi:10.1111/j.1365-2893.2006.00723.x 
68. Marshall N, Swain S. Cytotoxic CD4 T cells in antiviral immunity. J Biomed 
Biotechnol (2011) 2011:954602. doi:10.1155/2011/954602 
69. Sáez-Borderías A, Gumá M, Angulo A, Bellosillo B, Pende D, Lípez-Botet M. 
Expression and function of nkg2d in CD4+ T  cells specific for human 
cytomegalovirus. Eur J Immunol (2006) 36(12):3198–206. doi:10.1002/eji. 
200636682 
70. Soghoian D, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, 
et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection 
predict disease outcome. Sci Transl Med (2012) 29(4):123–5. doi:10.1126/
scitranslmed.3003165 
71. Rosa D, Ribeiro S, Cunha-Neto E. CD4+ T cell epitope discovery and ratio-
nal vaccine design. Arch Immunol Ther Exp (Warsz) (2010) 32(2):121–30. 
doi:10.1007/s00005-010-0067-0 
72. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, et  al. 
Generation of tissue-specific and promiscuous HLA ligand databases using 
DNA microarrays and virtual HLA class II matrices. Nat Biotechnol (1999) 
17(6):555–61. doi:10.1038/9858 
73. Singh H, Raghava G. Propred: prediction of HLA-DR binding sites. 
Bioinformatics (2001) 17(12):1236–7. doi:10.1093/bioinformatics/17.12. 
1236 
74. Hammer J, Belunis C, Bolin D, Papadopoulos J, Walsky R, Higelin J. High-
affinity binding of short peptides to major histocompatibility complex class II 
molecules by anchor combinations. Proc Natl Acad Sci U S A (1994) 91: 
4456–60. doi:10.1073/pnas.91.10.4456 
75. LK LI, Yoshida M, Sidney J, Shikanai-Yasuda M, Goldberg A, Juliano M, 
et al. In silico prediction of peptides binding to multiple HLA-DR molecules 
accurately identifies immunodominant epitopes from gp43 of Paracoccidioides 
brasiliensis frequently recognized in primary peripheral blood mononuclear 
cell responses from sensitized individuals. Mol Med (2003) 9:209–19. 
76. Ribeiro S, Rosa D, Fonseca S, Mairena E, Postól E, Oliveira S, et al. A vaccine 
encoding conserved promiscuous HIV CD4 epitopes induces broad T  cell 
responses in mice transgenic to multiple common HLA class II molecules. 
PLoS One (2010) 5(6):e11072. doi:10.1371/journal.pone.0011072 
77. Garcia T, Fonseca C, Pacifico L, Fdo VD, Marinho F, Penido M, et al. Peptides 
containing T  cell epitopes, derived from Sm14, but not from paramyosin, 
induce a Th1 type of immune response, reduction in liver pathology and 
partial protection against Schistosoma mansoni infection in mice. Acta Trop 
(2008) 106(3):162–7. doi:10.1016/j.actatropica.2008.03.003 
78. Whitton JL, Sheng N, Oldstone MBA, McKee TA. A “string-of-beads” vaccine, 
comprising linked mini genes, confers protection from lethal-dose virus 
challenge. J Virol (1993) 67(1):348–52. 
79. Mothe B. DNA-MVA Prime-Boost Vaccine Eliciting T-Cell Specificities 
Associated with HIV-1 Control is Highly Immunogenic in Mice and Breaks CTL 
Immuno-Dominance. Barcelona, Spain (2013).
80. Kopycinski J, Cheeseman H, Ashraf A, Gill D, Hayes P, Hannaman D. A 
DNA-based candidate HIV vaccine delivered via in  vivo electroporation 
induces CD4 responses toward the 4-7-binding v2 loop of HIV gp120 in 
healthy volunteers. Clin Vaccine Immunol (2012) 19(9):1557–9. doi:10.1128/
CVI.00327-12 
81. Mullins J. Refocusing CTL and Antibody Responses with p24 gag Conserved 
Elements Vaccines. Barcelona, Spain (2013).
82. Groot AD, Marcon L, Bishop E, Rivera D, Kutzler M, Weiner D, et al. HIV 
vaccine development by computer assisted design: the GAIA vaccine. Vaccine 
(2005) 23(17–18):2136–48. doi:10.1016/j.vaccine.2005.01.097
83. Rubsamen RM, Herst CV, Lloyd PM, Heckerman DE. Eliciting cytotoxic 
t-lymphocyte responses from synthetic vectors containing one or two 
epitopes in a c57bl/6 mouse model using peptide-containing biodegradable 
12
Cunha-Neto et al. Approach for Synthetic Vaccine Design against Zika
Frontiers in Immunology | www.frontiersin.org June 2017 | Volume 8 | Article 640
microspheres and adjuvants. Vaccine (2014) 32:4111–6. doi:10.1016/j.vaccine. 
2014.05.071 
84. Jain S, O’Hagan D, Singh M. The long-term potential of biodegradable poly 
(lactide co-glycolide) micro particles as the next-generation vaccine adjuvant. 
Expert Rev Vaccines (2007) 28:13. doi:10.1586/erv.11.126
85. Martin-Banderas LF, Flores-Mosquera M, Riesco-Chueca P, Rodriguez-Gil A, 
Cebolla A, Chávez S. Flow focusing: a versitile technology to produce 
size-controlled and specific-morphology microparticles. Small (2005) 1(7): 
688–92. doi:10.1002/smll.200500087
86. Waeckerle-Men Y, Allmen E, Gander B, Scandella E, Schlosser E, Schmidtke G. 
Encapsulation of proteins and peptides into biodegradable poly(d,l- lactide-
co-glycolide) microspheres prolongs and enhances antigen presentation 
by human dendritic cells. Vaccine (2006) 24(11):1847–57. doi:10.1016/ 
j.vaccine.2005.10.032
87. Salvadori L, Santana F, Marcos E. Frequency of alleles and haplotypes 
of the human leukocyte antigen system in Bauru, São Paulo, Brazil. 
Rev Bras Hematol Hemoter (2014) 36(2):108–14. doi:10.5581/1516-8484. 
20140026 
Conflict of Interest Statement: RR is CEO of Flow Pharma, Inc. RR, AM, TO, 
SC, and CH have received compensation in the form of cash and/or stock from 
Flow Pharma, Inc. All other authors declare that the research was conducted in the 
absence of any commercial or financial relationships that could be construed as a 
potential conflict of interest.
Copyright © 2017 Cunha-Neto, Rosa, Harris, Olson, Morrow, Ciotlos, Herst and 
Rubsamen. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
